Placebo News and Research

RSS

BioInvent completes enrollment in BI-204 phase IIa study for atherosclerosis

BioInvent International AB and its collaborator Genentech, a member of the Roche Group, announced today that all patients have completed enrollment in the GLACIER study, a phase IIa study with BI-204 in patients with stable atherosclerotic vascular disease.

2 Mar 2012

Positive results from AltheRx Solabegron Phase II study on overactive bladder

AltheRx Pharmaceuticals, a privately-held clinical development company, presented positive results from its Phase II study of Solabegron in overactive bladder (OAB) at the European Association of Urology Congress in Paris.

1 Mar 2012

Parkinson's drug Amantadine may help brain injury victims: Study

The study shows that Amantadine helps boost brain levels of dopamine, a neurotransmitter linked to arousal. And for patients who are in a vegetative state following a brain injury, the drug can help -- possibly by improving responsiveness during rehabilitation.

1 Mar 2012

Parasitic worms could offer new treatment hope for MS patients

Parasitic worms could offer a new treatment hope for patients suffering from the autoimmune disease multiple sclerosis, scientists believe.

1 Mar 2012

Ruxolitinib boosts QOL and survival for patients with myelofibrosis

A drug that relieves the severe symptoms of a life-threatening bone marrow cancer called myelofibrosis also improves the survival of patients with the disease, according to a phase III clinical trial published in the March 1 edition of New England Journal of Medicine.

1 Mar 2012

NEJM publishes results from two Jakafi Phase III studies on MF

The New England Journal of Medicine (NEJM) today published results from two Phase III studies (COMFORT-I and COMFORT-II) of Jakafi (ruxolitinib), a JAK1 and JAK2 inhibitor recently approved by the Food and Drug Administration (FDA) for the treatment of intermediate or high-risk myelofibrosis.

1 Mar 2012

Bayer receives FDA approval for lower dose formulation of ANGELIQ

Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a lower dose formulation of ANGELIQ (drospirenone and estradiol) tablets to treat moderate to severe vasomotor symptoms due to menopause in women who have a uterus.

29 Feb 2012

Biogen Idec announces new easier to use injection for multiple sclerosis

The Food and Drug Administration approved the company's Avonex pen, an injection designed to reduce pain and anxiety when patients self-administer the drug. The FDA also approved a new dosing schedule for the drug intended to reduce flu-like symptoms often associated with the drug.

29 Feb 2012

Creabilis initiates CT327 Phase IIb trial in psoriasis vulgaris

Creabilis SA, a European biotechnology company specialising in the development of treatments for dermatology, inflammation and pain, today announced the start of the Phase IIb global clinical trial of its lead product CT327 in patients with psoriasis vulgaris. Recruitment is progressing well.

29 Feb 2012

EpiCept fourth quarter revenue decreases to $0.2 million

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2011, and provided an update on the Company's key business initiatives.

29 Feb 2012

Quitting hormone therapy can lead to breast tumor regression

As soon as women quit hormone therapy, their rates of new breast cancer decline, supporting the hypothesis that stopping hormones can lead to tumor regression, according to a report e-published in Cancer Epidemiology, Biomarkers, & Prevention.

29 Feb 2012

Baxter commences CD34+ stem cell phase III trial in CMI

Baxter International Inc. announced today that it has initiated a phase III pivotal clinical trial to evaluate the efficacy and safety of adult autologous (an individual's own) CD34+ stem cells to increase exercise capacity in patients with chronic myocardial ischemia (CMI).

From Baxter International Inc. 28 Feb 2012

Single dose of Ritalin may raise awareness of mistakes: Study

The study, by Dr Rob Hester from the Department of Psychological Sciences and colleagues at the Queensland Brain Institute, investigated how the brain monitors ongoing behavior for performance errors – specifically failures of impulse control. This study found that a single dose of methylphenidate (Ritalin) results in significantly greater activity in the brain’s error monitoring network and improved volunteers’ awareness of their mistakes.

28 Feb 2012

Gedeon Richter and Forest Labs' cariprazine Phase III trials on schizophrenia meet primary endpoint

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced positive top-line results in 2 Phase III clinical trials of cariprazine (RGH-188) for the treatment of acute exacerbation of schizophrenia.

28 Feb 2012

TAK-875 as effective as glimepiride in treating type 2 diabetes

TAK-875, a new treatment for type 2 diabetes, improves blood sugar control and is equally effective as glimepiride, but has a significantly lower risk of creating a dangerous drop in blood sugar, called hypoglycemia, according to a new study.

27 Feb 2012

Glenmark Generics recalls batch of birth control pills

Drug manufacturer Glenmark Generics, announced last Friday, that it is recalling seven lots of birth control pills because in some packages, the pills were in the wrong order.

27 Feb 2012

Enrollment complete in Ikaria iNO Pivotal Phase III trial for BPD

Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced that it has enrolled the last patient into its Pivotal Phase III trial investigating the use of inhaled nitric oxide (iNO) in premature infants with bronchopulmonary dysplasia (BPD).

27 Feb 2012

Ritalin improves awareness of performance errors

People who take Ritalin are far more aware of their mistakes, a University of Melbourne study has found.

27 Feb 2012

New drug improves glycaemic control with minimum risk of hypoglycemia in type 2 diabetics

27 Feb 2012

FDA issues complete response letter for Watson's progesterone vaginal gel 8% NDA

Watson Pharmaceuticals, Inc. and Columbia Laboratories, Inc. today confirmed that, as expected, Watson has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA 22-139) for progesterone vaginal gel 8% for use in the reduction of risk of preterm birth in women with a singleton gestation and a short uterine cervical length in the mid-trimester of pregnancy.

27 Feb 2012